Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Northwestern University
Sponsor:
Collaborators:
Robert H. Lurie Cancer Center
National Comprehensive Cancer Network
GlaxoSmithKline
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT01465659
First received: October 4, 2011
Last updated: March 14, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2018
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)